InvestorsHub Logo
Followers 25
Posts 2423
Boards Moderated 0
Alias Born 07/25/2013

Re: None

Monday, 06/02/2014 7:35:15 AM

Monday, June 02, 2014 7:35:15 AM

Post# of 346182
02-Jun-2014 13:33 - PHASE 3 STUDY EVALUATING YERVOY® (IPILIMUMAB) FOR MELANOMA IN AN ADJUVANT SETTING MEETS PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL

02-Jun-2014 13:34 - BRISTOL-MYERS SQUIBB SAYS PHASE 3 STUDY EVALUATING YERVOY FOR MELANOMA IN ADJUVANT SETTING MEETS PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News